The limitations of this study include relatively small number of the patients analysed for the histopathology, lacking the examination on the effect of the GLP‐1R agonist on immune cells as mentioned earlier, and not evaluating its effect on the extramuscular involvements of inflammatory myopathies including the heart, skin, joint, and lung.35 The gene discussed is GLP1R; the disease is myopathy.